MAPT and Cognitive impairment: GFAP and Iba-1 (a microglia marker) expressions, as well as levels of IL-6, TNF-α, and IL-1β, were significantly reduced in the hippocampus and cortex of the mice treated with either 6.7 mg/mL or 20 mg/mL, in parallel exhibiting lower Aβ accumulation, tau hyperphosphorylation, and milder cognitive deficits [85].